Myozyme

Phase 3

Sanofi (SNYNF)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Glycogen Storage Disease Type II

SNYavalglucosidase alfa

Phase 3

View Full Landscape

Drug Information

Target Indication

Glycogen Storage Disease Type II

Clinical Trial

NCT00125879

Last updated: 2/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/28/2006

Myozyme

Myozyme is indicated for long-term enzyme-replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid-?-glucosidase deficiency). In patients with late-onset Pompe disease the evidence of efficacy is limited.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SNYNF

Sanofi

Biotechnology•North America•NASDAQ

Related Pipeline

IrbesartanPhase 3

Atrial Fibrillation

Teriflunomide (HMR1726)Phase 3

Multiple Sclerosis

DTaP-IPV-HB-PRP~T vaccinePhase 3

Diphtheria

Insulin glargine/lixisenatide Fixed Ratio CombinationPhase 3

Type 2 Diabetes

teriflunomide HMR1726Phase 3

Multiple Sclerosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts